Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Revenue (2018 - 2025)

BioNexus Gene Lab's Revenue history spans 8 years, with the latest figure at $2.5 million for Q3 2025.

  • For Q3 2025, Revenue fell 3.29% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $9.5 million, up 2.22%, while the annual FY2024 figure was $9.5 million, 2.66% down from the prior year.
  • Revenue for Q3 2025 was $2.5 million at BioNexus Gene Lab, up from $2.3 million in the prior quarter.
  • Across five years, Revenue topped out at $6.1 million in Q2 2021 and bottomed at $425802.0 in Q1 2021.
  • The 5-year median for Revenue is $2.5 million (2025), against an average of $2.7 million.
  • The largest YoY upside for Revenue was 15135.68% in 2021 against a maximum downside of 86.13% in 2021.
  • A 5-year view of Revenue shows it stood at $3.2 million in 2021, then decreased by 12.5% to $2.8 million in 2022, then decreased by 19.95% to $2.3 million in 2023, then grew by 11.03% to $2.5 million in 2024, then increased by 0.79% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Revenue are $2.5 million (Q3 2025), $2.3 million (Q2 2025), and $2.1 million (Q1 2025).